These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17363597)

  • 1. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
    Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
    Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.
    Rosso M; Polotskaia A; Bargonetti J
    Oncotarget; 2015 Oct; 6(33):34573-91. PubMed ID: 26416444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
    Arva NC; Talbott KE; Okoro DR; Brekman A; Qiu WG; Bargonetti J
    Ethn Dis; 2008; 18(2 Suppl 2):S2-1-8. PubMed ID: 18646312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
    Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
    Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
    Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
    Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
    Zhang X; Pageon L; Post SM
    Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
    Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
    Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
    Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
    Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk.
    Krekac D; Brozkova K; Knoflickova D; Hrstka R; Muller P; Nenutil R; Vojtesek B
    Oncology; 2008; 74(1-2):84-7. PubMed ID: 18547962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
    Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
    Walsh CS; Miller CW; Karlan BY; Koeffler HP
    Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
    Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
    Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.